山东东方海洋科技股份有限公司 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002086 证券简称：东方海洋 公告编号：2026-002 诉讼进展公告 本公司及董事会全体成员保证信息披露的真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1．案件所处的诉讼阶段：第一批投资者诉讼案件其中4名原告（綦领颜、王玲丽、王艳芳、张晖）案件 重一审判决。 2．上市公司所处的当事人地位：被告。 3．涉案的金额：4名原告合计对被告公司享有31,128,243.49元债权以及被告公司合计负担案件受理费 265,030元。 4．是否会对上市公司损益产生负面影响：公司前期已根据原审判决情况计提预计负债，对公司本期利 润或期后利润无重大影响。公司将持续密切关注案件后续进展，并严格按照相关规定及时履行信息披露 义务。 71,910元予以退回。《民事裁定书》【（2025）鲁民终178号】裁定如下：一、撤销青岛中院 【（2023）鲁02民初1163号】民事判决；二、本案发回青岛中院重审。公司预交的二审案件受理费 79,799元予以退回。《民事裁定书》【（2025）鲁民终179号】裁定如下：一、撤销青岛中院 【 ...

证券代码：002086 证券简称：东方海洋 公告编号：2026-002 山东东方海洋科技股份有限公司 诉讼进展公告 本公司及董事会全体成员保证信息披露的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1 特别提示 1．案件所处的诉讼阶段：第一批投资者诉讼案件其中4名原告（綦领颜、王玲丽、 王艳芳、张晖）案件重一审判决。 2．上市公司所处的当事人地位：被告。 3．涉案的金额：4名原告合计对被告公司享有31,128,243.49元债权以及被告公司 合计负担案件受理费265,030元。 4．是否会对上市公司损益产生负面影响：公司前期已根据原审判决情况计提预 计负债，对公司本期利润或期后利润无重大影响。公司将持续密切关注案件后续进展， 并严格按照相关规定及时履行信息披露义务。 一、第一批投资者诉讼案件 1．案件基本情况概述 山东东方海洋科技股份有限公司（以下简称"公司"）因涉嫌信息披露违法违规于 2019 年 9 月 27 日收到中国证券监督管理委员会山东监管局下发的《行政处罚决定书》 （【2019】9 号），部分中小投资者以"证券虚假陈述责任纠纷"为由向法院提起民事 诉讼。公司于 2025 年 4 月 2 ...

Core Viewpoint - The company is involved in a lawsuit with four plaintiffs who collectively hold a debt claim of 31.1282 million yuan against the company, with the company responsible for a case acceptance fee of 265,000 yuan [1] Group 1 - The lawsuit involves four plaintiffs: Qi Lingyan, Wang Lingli, Wang Yanfang, and Zhang Hui [1] - The company has previously recognized a provision for liabilities based on the original trial judgment, indicating that the current and future profits will not be significantly impacted [1] - The company will continue to monitor the progress of the case and fulfill its information disclosure obligations in a timely manner [1]

Core Viewpoint - Qian Dama International Holdings Limited is planning to go public on the Hong Kong Stock Exchange, aiming to expand its community fresh food retail business, which operates on a "discount day clear" model to minimize waste and ensure product freshness [1][19]. Group 1: Company Overview - Qian Dama is recognized as China's largest community fresh food chain and the largest meat retailer in South China, with projected revenues exceeding 11.7 billion RMB in 2024 [1][3]. - The company's business model focuses on providing fresh, high-quality cooking ingredients with a unique pricing strategy that offers discounts throughout the day [1][3]. - Qian Dama's revenue sources include animal protein (47.4%), fruits and vegetables (38.2%), and processed foods (13.3%) [3][4]. Group 2: Market Position and Competition - The community fresh food retail sector in China is highly fragmented, with Qian Dama holding only a 2.2% market share among the top five brands, which collectively account for 7.3% of the market [3][6]. - Qian Dama competes with major players like Yonghui Supermarket and various fresh food e-commerce platforms [2][3]. Group 3: Financial Performance - Qian Dama's revenue for 2023, 2024, and the first nine months of 2025 is approximately 11.744 billion RMB, 11.788 billion RMB, and 8.359 billion RMB, respectively, with net profits of 169 million RMB, 288 million RMB, and a loss of 288 million RMB [9][15]. - The company's gross margin has shown slight improvement, with rates of 9.8%, 10.2%, and 11.3% over the same periods [13][14]. Group 4: Business Model and Operations - Over 90% of Qian Dama's revenue comes from franchisees, with a decline in the number of self-operated stores from 81 in 2023 to 40 by September 2025 [11][15]. - The company primarily sources products from domestic agricultural bases and qualified suppliers, focusing on cost-effective procurement and logistics [11][12]. Group 5: Future Plans and Challenges - The IPO proceeds will be used for expanding the store network, enhancing product offerings, improving supply chain efficiency, and upgrading digital infrastructure [19]. - The company faces challenges in balancing store expansion, consumer affordability, and franchisee interests amid a competitive and slowing market [19].

Group 1 - The core viewpoint emphasizes the importance of collaboration between government and courts to enhance social governance efficiency in Shandong Province [2][3] - A new mechanism for regular collaboration between government and courts has been established, covering provincial, municipal, and county levels [2][3] - The first coordination meeting led to the successful restructuring of a listed company, resolving over 3 billion yuan in debts and stabilizing over 1,000 related employees [3][4] Group 2 - The collaboration has resulted in significant achievements, such as the successful mediation of 1,500 cases in the construction sector, saving 60 million yuan in litigation costs [5] - The initiative aims to transform individual case rulings into broader regulatory frameworks, enhancing overall governance effectiveness [5][6] - The establishment of a judicial recommendation for the development of offshore ranching has facilitated the creation of inspection standards and legislative plans [6] Group 3 - Future efforts will focus on addressing deeper institutional challenges, leveraging the strengths of both administrative and judicial bodies for mutual benefit [7][8] - Data sharing between government and judicial entities is identified as a critical area for further collaboration [8] - The initiative has contributed to a decrease in administrative litigation cases, indicating improved awareness and capability in lawful governance [9]

每经AI快讯，1月21日，东方海洋公告，全资子公司艾维可生物科技有限公司收到国家药品监督管理局 的医疗器械注册证，其自主研发的幽门螺杆菌（HP）抗原检测试剂盒（胶体金法）获准上市，适用于 体外定性检测人粪便样本中的幽门螺杆菌抗原。上述产品获准上市进一步丰富了艾维可生物科技有限公 司在临床检测领域的产品线。但鉴于艾维可生物科技有限公司今年对公司的业绩影响较小，本次获批产 品的投产及对公司业绩的后续影响具有不确定性。产品获证后还未投入生产，实际销售情况受市场拓展 力度及市场实际需求等多重因素影响，目前尚无法预测其对公司未来业绩的具体影响，请广大投资者注 意投资风险。 ...

东方海洋1月21日公告，公司全资子公司艾维可生物科技有限公司幽门螺杆菌抗原 检测试剂盒获得国家 药品监督管理局颁发的 医疗器械注册证。本试剂盒用于体外定性检测人粪便样本中的幽门螺杆菌抗 原。上述产品获准上市，进一步丰富了艾维可生物科技有限公司在临床检测领域的产品线。但鉴于艾维 可生物科技有限公司今年对公司的业绩影响较小，上述产品的投产以及对公司业绩的后续影响具有不确 定性。同时，上述产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场实际需求等多重因 素影响，目前尚无法预测上述产品对公司未来业绩的具体影响。 ...

证券代码：002086 证券简称：东方海洋 公告编号：2026-001 山东东方海洋科技股份有限公司 关于全资子公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或者重大遗漏。 特别提示： 2. 本次产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测上述获批产品对公司未来业绩的具体 影响，请广大投资者注意投资风险。 请广大投资者充分阅读本公告正文表述的相关风险事项，公司特别提示投资 者理性投资。 山东东方海洋科技股份有限公司（以下简称"公司"）全资子公司艾维可生物 科技有限公司自主研发的幽门螺杆菌（HP）抗原检测试剂盒（胶体金法）于近 日取得了国家药品监督管理局的注册批准，获得医疗器械注册证，具体情况如下： 一、产品信息 1、幽门螺杆菌（HP）抗原检测试剂盒（胶体金法） | 产品名称 | 幽门螺杆菌（HP）抗原检测试剂盒（胶体金法） | | | | | --- | --- | --- | --- | --- | | 注册证编号 | 国械注准 20263400136 | | | | | 注册人名称 | ...

东方海洋1月21日公告，公司全资子公司艾维可生物科技有限公司幽门螺杆菌（HP）抗原检测试剂盒 （胶体金法）获得国家药品监督管理局颁发的医疗器械注册证。本试剂盒用于体外定性检测人粪便样本 中的幽门螺杆菌抗原。上述产品获准上市，进一步丰富了艾维可生物科技有限公司在临床检测领域的产 品线。但鉴于艾维可生物科技有限公司今年对公司的业绩影响较小，上述产品的投产以及对公司业绩的 后续影响具有不确定性。同时，上述产品获证后还未投入生产，其实际销售情况受市场拓展力度及市场 实际需求等多重因素影响，目前尚无法预测上述产品对公司未来业绩的具体影响。 ...

证券日报网讯1月5日，东方海洋（002086）在互动平台回答投资者提问时表示，公司严格按照法律法规 及监管要求及时进行信息披露，不存在应披露而未披露的信息。 ...